Jeynes to Chair Oncology Board
Mosaic Therapeutics Appoints Dr. Allison Jeynes as Board Chair for Clinical-Stage Transition
Anonymous
Mosaic Therapeutics has named Dr Allison Jeynes as Chair of the Board, the oncology company announced Caledonian Record. The appointment is designed to help Mosaic move from a research-stage firm into a clinical-stage company developing cancer treatments.
Jeynes is a UK-trained oncologist with more than 30 years of drug development and executive experience Leader Post. She has led global teams to achieve a 100% success rate from Phase 3 trials through to FDA approval across oncology, immunology, and respiratory medicine.
Jeynes Brings Three Decades of FDA Approval Success
Jeynes has a rare track record in drug development. She guided multiple programs from late-stage clinical trials all the way to FDA approval — without a single failure Calgary Sun. That 100% success rate spans three major fields: cancer, immune diseases, and respiratory conditions.
She trained as an oncologist in the UK before moving into industry leadership roles Whitecourt Star. Her background combines hands-on medical practice with decades of executive decision-making — a mix Mosaic sees as critical for its next phase of growth.
Mosaic Pushes Toward First Clinical Trials in Oncology
Mosaic Therapeutics is an oncology company based in Cambridge, England Caledonian Record. It is now working to move its programs from early research into human clinical trials. Bringing in an experienced chair is a key step in that transition.
Clinical-stage companies run drug trials in patients for the first time. That shift brings greater regulatory scrutiny, higher costs, and more complex decision-making. Having a chair who has done it before — repeatedly and successfully — gives Mosaic a significant advantage Owen Sound Sun Times.
Syncona Director Hodgkin Stays on the Board
Edward Hodgkin will remain on Mosaic's board as a Non-Executive Director Seaforth Huron Expositor. Hodgkin serves as a Non-Executive Director at Syncona Investment Management Limited, a life sciences investor focused on building and backing biotech companies.
Syncona's continued involvement signals ongoing investor confidence in Mosaic's direction Woodstock Sentinel Review. Hodgkin's role keeps a direct line open between the company and one of its key backers as it prepares for the costly work of clinical development.
Leadership Overhaul Sets Stage for Cancer Drug Push
The appointment of Jeynes as chair marks a clear leadership shift at Mosaic The Craig and Canyon. Companies preparing for clinical trials often bring in senior figures with regulatory and commercial experience to guide strategy and attract further investment.
With Jeynes at the helm and Hodgkin maintaining board continuity, Mosaic now has a leadership team built for the challenges ahead Calgary Sun. The company's next milestone will be moving its oncology programs into human trials — a step that could define its future.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
8
Articles
8
Reach
8
A
AnonymousAuthor
